Replagal Advisory Committee Meeting Possible By End Of The Year, TKT Says
Executive Summary
FDA's Endocrinologic & Metabolic Drugs Advisory Committee may consider Transkaryotic Therapies' Fabry Disease treatment, Replagal (agalsidase alfa), before the end of the year, TKT said
You may also be interested in...
TKT Replagal Renal Function Trial To Be Submitted By Year-End
Transkaryotic Therapies will submit data from a Phase III trial evaluating renal function in Fabry disease patients treated with Replagal by the end of the year, CEO Richard Selden, MD/PhD, said Oct. 30
Replagal and Fabrazyme reviews
Genzyme's Fabrazyme (agalsidase beta) and TKT's Replagal (agalsidase alfa) will be reviewed by FDA's Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13 and 14. The committee was originally slated to review the BLAs on Sept. 26-27. The delay apparently resulted from concerns raised by TKT about potential conflicts of interest among certain committee-invited guests (1"The Pink Sheet" Oct. 7, p. 23). The meeting will begin at 8 a.m. both days at the Holiday Inn in Bethesda, Md. [To view a 2webcast/video of each of these meetings, go to FDAAdvisoryCommittee.com]....
TKT Replagal Renal Function Trial To Be Submitted By Year-End
Transkaryotic Therapies will submit data from a Phase III trial evaluating renal function in Fabry disease patients treated with Replagal by the end of the year, CEO Richard Selden, MD/PhD, said Oct. 30